ImaRx CEO Evan Unger, M.D., to Speak at BIO 2005 on Nanotechnology
Members of the nanotechnology panel will include biotechnology and pharmaceutical executives and venture capitalists who will discuss the development of leading nanotechnologies for drug delivery and less invasive treatment of cancer and cardiovascular disease, as well as the rise in investor interest in nanotechnology companies and the convergence of biotechnology and nanotechnology. The panel will also discuss possible business models that offer attractive investment opportunities in the nanotech sector and collaborative efforts between large pharmaceutical and nanotechnology companies.
About ImaRx and NanoInvasive(TM) Medicine
ImaRx, a privately-held biopharmaceutical company, develops NanoInvasive therapies for the treatment of cardiovascular disease, CNS disease, and cancers. The Company's lead product, SonoLysis(TM), combines the power of ultrasound with proprietary nanobubbles to locally dissolve blood clots without the use of invasive surgery or potentially dangerous lytic drugs. SonoLysis is currently being studied in a Phase II trial for the treatment of stroke and Phase I/II trials for the treatment of deep vein thrombosis and peripheral arterial occlusive disease.